157 related articles for article (PubMed ID: 37769168)
1. Predictors of cardiovascular risk in familial hypercholesterolemia.
Romero-Jiménez MJ; Mansilla-Rodríguez ME; Gutiérrez-Cortizo EN
Curr Opin Lipidol; 2023 Dec; 34(6):272-277. PubMed ID: 37769168
[TBL] [Abstract][Full Text] [Related]
2. Predictors of cardiovascular risk in familial hypercholesterolemia.
Romero-Jiménez MJ; Mansilla-Rodríguez ME
Curr Opin Endocrinol Diabetes Obes; 2024 May; ():. PubMed ID: 38716720
[TBL] [Abstract][Full Text] [Related]
3. Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?
Mata P; Alonso R; Pérez de Isla L
Curr Opin Lipidol; 2018 Dec; 29(6):445-452. PubMed ID: 30382952
[TBL] [Abstract][Full Text] [Related]
4. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study).
Pérez de Isla L; Alonso R; Mata N; Fernández-Pérez C; Muñiz O; Díaz-Díaz JL; Saltijeral A; Fuentes-Jiménez F; de Andrés R; Zambón D; Piedecausa M; Cepeda JM; Mauri M; Galiana J; Brea Á; Sanchez Muñoz-Torrero JF; Padró T; Argueso R; Miramontes-González JP; Badimón L; Santos RD; Watts GF; Mata P
Circulation; 2017 May; 135(22):2133-2144. PubMed ID: 28275165
[TBL] [Abstract][Full Text] [Related]
5. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.
Miname MH; Bittencourt MS; Nasir K; Santos RD
Curr Opin Lipidol; 2019 Apr; 30(2):82-87. PubMed ID: 30649025
[TBL] [Abstract][Full Text] [Related]
6. Metabolic systems approaches update molecular insights of clinical phenotypes and cardiovascular risk in patients with homozygous familial hypercholesterolemia.
Du Z; Li F; Jiang L; Li L; Du Y; Yu H; Luo Y; Wang Y; Sun H; Hu C; Li J; Yang Y; Jiao X; Wang L; Qin Y
BMC Med; 2023 Jul; 21(1):275. PubMed ID: 37501168
[TBL] [Abstract][Full Text] [Related]
7. SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia.
Gallo A; Charriere S; Vimont A; Chapman MJ; Angoulvant D; Boccara F; Cariou B; Carreau V; Carrié A; Bruckert E; Béliard S;
Atherosclerosis; 2020 Aug; 306():41-49. PubMed ID: 32688103
[TBL] [Abstract][Full Text] [Related]
8. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
Miname MH; Santos RD
Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
[TBL] [Abstract][Full Text] [Related]
9. Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service.
Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C
Eur J Prev Cardiol; 2017 May; 24(8):867-875. PubMed ID: 28186442
[TBL] [Abstract][Full Text] [Related]
10. Predicting cardiovascular disease in familial hypercholesterolemia.
Paquette M; Baass A
Curr Opin Lipidol; 2018 Aug; 29(4):299-306. PubMed ID: 29708923
[TBL] [Abstract][Full Text] [Related]
11. Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry.
Cuchel M; Lee PC; Hudgins LC; Duell PB; Ahmad Z; Baum SJ; Linton MF; de Ferranti SD; Ballantyne CM; Larry JA; Hemphill LC; Kindt I; Gidding SS; Martin SS; Moriarty PM; Thompson PP; Underberg JA; Guyton JR; Andersen RL; Whellan DJ; Benuck I; Kane JP; Myers K; Howard W; Staszak D; Jamison A; Card MC; Bourbon M; Chora JR; Rader DJ; Knowles JW; Wilemon K; McGowan MP
J Am Heart Assoc; 2023 May; 12(9):e029175. PubMed ID: 37119068
[TBL] [Abstract][Full Text] [Related]
12. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.
Santos RD; Gidding SS; Hegele RA; Cuchel MA; Barter PJ; Watts GF; Baum SJ; Catapano AL; Chapman MJ; Defesche JC; Folco E; Freiberger T; Genest J; Hovingh GK; Harada-Shiba M; Humphries SE; Jackson AS; Mata P; Moriarty PM; Raal FJ; Al-Rasadi K; Ray KK; Reiner Z; Sijbrands EJ; Yamashita S;
Lancet Diabetes Endocrinol; 2016 Oct; 4(10):850-61. PubMed ID: 27246162
[TBL] [Abstract][Full Text] [Related]
13. Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events.
D'Erasmo L; Minicocci I; Di Costanzo A; Pigna G; Commodari D; Ceci F; Montali A; Brancato F; Stanca I; Nicolucci A; Ascione A; Galea N; Carbone I; Francone M; Maranghi M; Arca M
J Am Heart Assoc; 2021 May; 10(9):e018932. PubMed ID: 33890476
[TBL] [Abstract][Full Text] [Related]
14. Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia.
Paquette M; Bernard S; Cariou B; Hegele RA; Genest J; Trinder M; Brunham LR; Béliard S; Baass A
J Clin Lipidol; 2023; 17(3):376-383. PubMed ID: 37003850
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
Yamashita S; Masuda D; Harada-Shiba M; Arai H; Bujo H; Ishibashi S; Daida H; Koga N; Oikawa S
J Atheroscler Thromb; 2022 May; 29(5):608-638. PubMed ID: 33980760
[TBL] [Abstract][Full Text] [Related]
16. Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease.
Hedegaard BS; Bork CS; Kaltoft M; Klausen IC; Schmidt EB; Kamstrup PR; Langsted A; Nordestgaard BG
J Am Coll Cardiol; 2022 Nov; 80(21):1998-2010. PubMed ID: 36396201
[TBL] [Abstract][Full Text] [Related]
17. Screening and management of familial hypercholesterolemia.
Santos RD
Curr Opin Cardiol; 2019 Sep; 34(5):526-530. PubMed ID: 31393421
[TBL] [Abstract][Full Text] [Related]
18. Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia.
Paquette M; Bernard S; Cariou B; Hegele RA; Genest J; Trinder M; Brunham LR; Béliard S; Baass A
Arterioscler Thromb Vasc Biol; 2021 Oct; 41(10):2632-2640. PubMed ID: 34433300
[TBL] [Abstract][Full Text] [Related]
19. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry.
Pérez de Isla L; Arroyo-Olivares R; Alonso R; Muñiz-Grijalvo O; Díaz-Díaz JL; Zambón D; Fuentes F; Mata N; Piedecausa M; Mañas MD; Sánchez Muñoz-Torrero JF; Miramontes-González JP; de Andrés R; Mauri M; Aguado R; Brea Á; Cepeda JM; Vidal-Pardo JI; Martínez-Faedo C; Barba MÁ; Argüeso R; Ruiz-Pérez E; Michán A; Arrieta F; Riestra Fernández M; Pérez L; Pinilla JM; Díaz-Soto G; Pintó X; Padró T; Badimón L; Mata P;
Rev Esp Cardiol (Engl Ed); 2020 Oct; 73(10):828-834. PubMed ID: 32201274
[TBL] [Abstract][Full Text] [Related]
20. Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype.
Ramos R; Masana L; Comas-Cufí M; García-Gil M; Martí-Lluch R; Ponjoan A; Plana N; Alves-Cabratosa L; Marrugat J; Elosua R; Dégano IR; Gomez-Marcos MA; Zamora A
Atherosclerosis; 2020 Jan; 292():42-51. PubMed ID: 31759248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
